Document is current
Any future updates will be listed below
-
Authors
Gerhardt, Teresa https://orcid.org/0000-0002-6144-5279
Jacob, Walter https://orcid.org/0000-0001-9649-4989
Gaebel, Lena
Heiser, Merlin https://orcid.org/0000-0001-5232-0688
Wolfram, Christopher https://orcid.org/0009-0002-8113-9102
Huynh, Pacific
Nakao, Tetsushi https://orcid.org/0000-0001-9979-2682
Gindri Dos Santos, Bernardo
Toh, Pamela
Douglas, Aaron https://orcid.org/0000-0002-8812-9575
Brisnovali, Niki F.
Radkevich, Emir
Uddin, Md Mesbah https://orcid.org/0000-0003-1846-0411
Yates, Abi G.
Khamhoung, Annie
Yatim, Nader https://orcid.org/0000-0001-5326-1624
Gianeselli, Matteo https://orcid.org/0000-0003-3726-3595
Kiss, Máté G. https://orcid.org/0000-0002-9215-8328
Goswami, Sukanya
Nelson, Daniella
Chen, Rachel
D’Souza, Darwin
Chen, Zhihong https://orcid.org/0000-0001-7403-7015
Kim-Schulze, Seunghee https://orcid.org/0000-0003-0192-4400
Fidler, Trevor https://orcid.org/0000-0002-0758-9984
Ezzat, Daniel https://orcid.org/0009-0002-6850-4275
Khurshid, Shaan
Bick, Alexander G. https://orcid.org/0000-0001-5824-9595
Natarajan, Pradeep https://orcid.org/0000-0001-8402-7435
Ellinor, Patrick T.
Rajbhandari, Abha K. https://orcid.org/0000-0002-5596-8735
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Swirski, Filip K. https://orcid.org/0000-0002-3163-9152
Cohen, Oren https://orcid.org/0009-0004-2827-9063
Goedeke, Leigh
Honigberg, Michael C. https://orcid.org/0000-0001-8630-5021
McAlpine, Cameron S. https://orcid.org/0000-0002-9832-6345
- License Information
-
More Information
Article History
Received: 4 May 2025
Accepted: 8 May 2026
First Online: 10 June 2026
Competing interests
: C.S.M. is a consultant for Granite Bio, unrelated to the present work. M.C.H. reports consulting fees from Comanche Biopharma; site principal investigator work and advisory board service for Novartis; and research support from Genentech, unrelated to the present work. S.K. has received sponsored research support from Bayer AG, unrelated to the present work. P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Cleerly, Genentech/Roche, Ionis, Novartis and Silence Therapeutics; personal fees from Allelica, Apple, AstraZeneca, Bain Capital, Blackstone Life Sciences, Bristol Myers Squibb, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, Merck, Novartis, Novo Nordisk, TenSixteen Bio and Tourmaline Bio; equity in Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. The other authors declare no competing interests.
